¼¼°èÀÇ ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀå
Drug Device Combination Products
»óǰÄÚµå : 1563845
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 196 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,789,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀº 2030³â±îÁö 1,587¾ï ´Þ·¯¿¡ µµ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

2023³â¿¡ 1,148¾ï ´Þ·¯·Î ÃßÁ¤µÈ ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀº 2030³â¿¡´Â 1,587¾ï ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °æÇÇ ÆÐÄ¡´Â º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.5%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 534¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈíÀԱ⠺ι®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 306¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀº 2023³â¿¡ 306¾ï ´Þ·¯·Î ÃßÁ¤µÆ½À´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 362¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 8.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 1.8%¿Í 4.9%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀå- ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°À̶õ ¹«¾ùÀΰ¡, ¿Ö Áß¿äÇѰ¡?

ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°Àº ´Ù¾çÇÑ º´¸®¿¡ ´ëÇÑ Ä¡·áÀÇ È¿´É, ¾ÈÀü¼º, Æí¸®¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ¾àÁ¦, ÀåÄ¡, ¶§·Î´Â »ý¹°Á¦Á¦¸¦ Á¶ÇÕÇÑ Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°Àº ½Ã³ÊÁö È¿°ú¸¦ ÅëÇÑ Ä¡·á ¼º°ú Çâ»ó, ¾à¹° Àü´ÞÀÇ Ç¥ÀûÈ­, ¹æÃâ Á¦¾î, ºÎÀÛ¿ë °¨¼Ò µîÀ» Á¦°øÇϱ⠶§¹®¿¡ ÀÇ·á »ê¾÷¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀϹÝÀûÀÎ ¿¹·Î´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ®, ÇÁ¸®Çʵå ÁÖ»ç±â, ÈíÀÔ±â, °æÇÇ ÆÐÄ¡, ¾à¹° ÄÚÆÃÀÌ Àû¿ëµÈ ÀÓº£µðµå ÀåÄ¡ µîÀÌ ÀÖ½À´Ï´Ù. ¾à¹°°ú ÀåÄ¡ÀÇ ÅëÇÕÀº Á¤È®¼º, °ü¸®, ȯÀÚÀÇ ¾îµå·¹½ÌÀÌ Áß¿äÇÑ ¸¸¼º Áúȯ °ü¸®, Á¾¾çÇÐ, ½ÉÇ÷°ü Ä¡·á¿¡ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù. °³º°È­µÈ È¿°úÀûÀÎ Ä¡·á¹ý ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó, ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°Àº Çö´ë ÇコÄɾ ÇʼöÀûÀÎ ¿ä¼Ò°¡ µÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ Áøº¸´Â ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀ» ¾î¶»°Ô °ßÀÎÇϰí Àִ°¡?

±â¼úÀÇ Áøº¸´Â ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀÇ ¼ºÀå°ú °³Ã´À» Å©°Ô µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡, ½º¸¶Æ® ÈíÀÔ±â, »ýü Èí¼ö¼º ½ºÅÙÆ®¿Í °°Àº ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº ȯÀÚÀÇ ÄÄÇöóÀÌ¾ð½º¿Í Ä¡·á È¿°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¼¾¼­ ¹× ¹«¼± ¿¬°áÀ» Æ÷ÇÔÇÑ µðÁöÅÐ °Ç°­ ±â¼úÀÇ µµÀÔÀº ȯÀÚÀÇ ¾îµå·¹½Ì ¹× ¾à¹° Àü´ÞÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô Çϰí Ä¡·á °èȹÀ» ÃÖÀûÈ­Çϱâ À§ÇÑ ±ÍÁßÇÑ µ¥ÀÌÅ͸¦ ÀÇ·á Á¦°ø¾÷ü¿¡°Ô Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ »ýüÀûÇÕ¼º °íºÐÀÚ ¹× ÇÏÀ̵å·Î°Ö°ú °°Àº ½Å¼ÒÀçÀÇ °³¹ßÀº ÀÓº£µðµå µð¹ÙÀ̽ºÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Çâ»ó½ÃŰ°í ºÎÀÛ¿ëÀÇ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù. ¶ÇÇÑ ÄÞºñ³×ÀÌ¼Ç Á¦Ç°ÀÇ Á¦Á¶¿¡ 3D ÇÁ¸°ÆÃ ±â¼úÀ» »ç¿ëÇÏ¿© º¸´Ù Á¤±³ÇÑ ¸ÂÃãÈ­¿Í Á¤È®¼ºÀ» Á¦°øÇÏ¿© °³º° ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸¿¡ ºÎÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ Áøº¸´Â ¹ÌÃæÁ· ¿ä±¸¿¡ ´ëÀÀÇÏ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

±ÔÁ¦°æ·Î¿Í ½ÃÀå ¿ªÇÐÀº ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°¿¡ ¾î¶² ¿µÇâÀ» ÁÖ°í Àִ°¡?

ÀǾàǰ/ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°ÀÇ ±ÔÁ¦ »óȲÀº º¹ÀâÇϸç, À̵é Á¦Ç°Àº ÀǾàǰ°ú ÀÇ·á±â±âÀÇ ±ÔÁ¦ ±âÁØÀ» ¸ðµÎ ÃæÁ·ÇØ¾ß ÇÕ´Ï´Ù. FDA¿Í EMA¿Í °°Àº ±ÔÁ¦±â°üÀº º´¿ëÁ¦Ç°ÀÇ ½ÂÀΰúÁ¤À» °£¼ÒÈ­Çϰí, ¾ÈÀü¼º°ú À¯È¿¼ºÀ» È®º¸Çϸ鼭 ½ÃÀå ÅõÀÔ±îÁöÀÇ ½Ã°£À» ´ÜÃàÇϱâ À§ÇÑ ±¸Ã¼ÀûÀÎ °¡À̵å¶óÀÎÀ» Ã¥Á¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©Àº Á¦Á¦ÀÇ °³¹ß°ú »ó¾÷È­¸¦ À§ÇÑ ¸íÈ®ÇÑ °æ·Î¸¦ Á¦°øÇÔÀ¸·Î½á ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½Â, °í·ÉÈ­, Àúħ½ÀÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä µî ½ÃÀå ¿ªÇÐÀº ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç°ÀÇ Ã¤¿ëÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Áß½ÉÀÇ Ä¡·á¿¡ ´ëÇÑ °ü½É°ú ºñ¿ë È¿°úÀûÀÎ °Ç°­ °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺Àº Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÔ¿ø ±â°£À» ´ÜÃàÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Á¦Ç°ÀÇ »ç¿ëÀ» ÃËÁøÇÕ´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº?

ÀǾàǰ-ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀº ±â¼úÀÇ Áøº¸, À¯¸®ÇÑ ±ÔÁ¦ ȯ°æ, ¸¸¼º ÁúȯÀÇ À¯º´·üÀÇ »ó½Â µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº ȯÀÚÀÇ ÄÄÇöóÀÌ¾ð½º¿Í Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ´Â ³·Àº ħ½À Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ Çコ ±â¼ú°ú ½º¸¶Æ® ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ, º´¿ë Á¦Ç°ÀÇ À¯È¿¼º°ú ÆíÀǼºÀ» ³ô¿©, Çコ Äɾî ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚ ¸ðµÎ¿¡°Ô º¸´Ù ¸Å·ÂÀûÀÎ °ÍÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï±¹ ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ÀÌ·¯ÇÑ Á¦Ç°ÀÇ °³¹ß°ú ä¿ëÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç, ÀÇ·á±â±â Á¦Á¶¾÷ü, ¿¬±¸±â°üÀÇ Àü·«Àû Á¦ÈÞ´Â ±â¼ú Çõ½Å°ú ½ÃÀå ¼ºÀåÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº Àç·á °úÇÐ ¹× ¾àÁ¦ ó¹æ ±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸¿Í ÇÔ²² ÀǾàǰ°ú ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ½ÃÀåÀ» ÀüÁø½Ã۰í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(Àü 46°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Drug Device Combination Products Market to Reach US$158.7 Billion by 2030

The global market for Drug Device Combination Products estimated at US$114.8 Billion in the year 2023, is expected to reach US$158.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Transdermal Patches, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$53.4 Billion by the end of the analysis period. Growth in the Inhalers segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.6 Billion While China is Forecast to Grow at 8.3% CAGR

The Drug Device Combination Products market in the U.S. is estimated at US$30.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$36.2 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Drug Device Combination Products Market - Key Trends & Drivers Summarized

What Are Drug Device Combination Products And Why Are They Important?

Drug device combination products are innovative therapeutic solutions that combine drugs, devices, and sometimes biologics to improve the efficacy, safety, and convenience of treatment for various medical conditions. These products are increasingly gaining importance in the healthcare industry as they offer enhanced treatment outcomes through synergistic effects, providing targeted drug delivery, controlled release, and reduced side effects. Common examples include drug-eluting stents, prefilled syringes, inhalers, transdermal patches, and implantable devices with drug coatings. The integration of drugs and devices is particularly valuable in chronic disease management, oncology, and cardiovascular treatments, where precision, control, and patient adherence are critical. As the demand for personalized and effective treatment options grows, drug device combination products are becoming an essential component of modern healthcare.

How Are Technological Advancements Driving The Drug Device Combination Products Market?

Technological advancements are significantly driving the growth and development of the drug device combination products market. Innovations in drug delivery systems, such as microneedle patches, smart inhalers, and bioresorbable stents, are enhancing patient compliance and therapeutic effectiveness. The incorporation of digital health technologies, including sensors and wireless connectivity, is enabling real-time monitoring of patient adherence and drug delivery, providing valuable data to healthcare providers for optimizing treatment plans. Additionally, the development of novel materials, such as biocompatible polymers and hydrogels, is improving the safety and efficacy of implantable devices, reducing the risk of adverse reactions. The use of 3D printing technology in manufacturing combination products is also allowing for greater customization and precision, catering to the specific needs of individual patients. These technological advancements are transforming the market landscape by offering innovative solutions that address unmet clinical needs.

How Are Regulatory Pathways And Market Dynamics Impacting Drug Device Combination Products?

The regulatory landscape for drug device combination products is complex, as these products must meet the standards of both drug and device regulations. Regulatory bodies such as the FDA and EMA are increasingly developing specific guidelines to streamline the approval process for combination products, ensuring safety and efficacy while reducing time to market. These regulatory frameworks are encouraging innovation by providing clearer pathways for the development and commercialization of combination products. Market dynamics, such as the rising prevalence of chronic diseases, the aging population, and the demand for minimally invasive treatments, are further driving the adoption of drug device combination products. The increasing focus on patient-centric care and the need for cost-effective healthcare solutions are also promoting the use of these products, as they offer improved treatment outcomes and reduced hospital stays.

What Factors Are Driving The Growth Of The Drug Device Combination Products Market?

The growth in the drug device combination products market is driven by several factors, including technological advancements, favorable regulatory environments, and the rising prevalence of chronic diseases. A key driver is the increasing demand for minimally invasive treatments that offer better patient compliance and outcomes. The growing adoption of digital health technologies and smart drug delivery systems is also enhancing the effectiveness and convenience of combination products, making them more attractive to both healthcare providers and patients. Additionally, the expansion of healthcare infrastructure in emerging markets and the increasing focus on personalized medicine are supporting the development and adoption of these products. Strategic collaborations between pharmaceutical companies, medical device manufacturers, and research institutions are further propelling innovation and market growth. These factors, coupled with the continuous advancement of materials science and drug formulation technologies, are driving the global market for drug device combination products forward.

Select Competitors (Total 46 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â